CN100540013C - Herba Euphorbiae Humifusae effective site and effective ingredient thereof are in the purposes of the medicine of preparation antifungic action - Google Patents
Herba Euphorbiae Humifusae effective site and effective ingredient thereof are in the purposes of the medicine of preparation antifungic action Download PDFInfo
- Publication number
- CN100540013C CN100540013C CNB2006101008171A CN200610100817A CN100540013C CN 100540013 C CN100540013 C CN 100540013C CN B2006101008171 A CNB2006101008171 A CN B2006101008171A CN 200610100817 A CN200610100817 A CN 200610100817A CN 100540013 C CN100540013 C CN 100540013C
- Authority
- CN
- China
- Prior art keywords
- herba euphorbiae
- euphorbiae humifusae
- effective
- medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of Herba Euphorbiae Humifusae effective site and effective ingredient thereof purposes, adopt conventional water extraction or alcohol extracting method or macroporous resin extraction or organic solvent extraction to obtain Herba Euphorbiae Humifusae effective site and effective ingredient as the medicine of preparation antifungic action.Use 41 routine superficial fungi patients' of Herba Euphorbiae Humifusae extract (effective site and effective ingredient thereof) treatment clinical observation result to show, said preparation significantly improves superficial fungi patient's clinical symptoms and sign, clinical total effective rate is 97.92%, cure rate is 85.92%, effective percentage is 12.0%, invalid is 2.25%, and no obvious toxic-side effects is the good medicine of treatment superficial fungi disease.
Description
Technical field
The present invention relates to the purposes of medicine of medicinal application, the especially antifungic action of a kind of Herba Euphorbiae Humifusae effective site and effective ingredient thereof.
Background technology
Herba Euphorbiae Humifusae is the dry herb of euphorbia plant Radix seu Caulis Parthenocissi tricuspidatae EuphorbiahumifusaWilld. or Herba Euphorbiae supinae EuphorbiamaculataL..Function with heat-clearing and toxic substances removing, cooling blood for hemostasis clinically at present is used for the treatment of bacillary dysentery, enteritis, viral hepatitis, hemoptysis, hematuria more, has blood in stool etc.But effective site of relevant Herba Euphorbiae Humifusae and effective ingredient thereof do not appear in the newspapers as yet as the medicinal usage of preparation antifungic action.
In recent years, the sickness rate persistence of superficial mycosis increases, and especially at border district sickness rate height, its pathogenic bacterium kind is a lot, is mainly trichophyton, trichophyton gypseum etc.Although at present antifungal new drug (for oral administration, external) is more, because superficial mycosis is to the high-affinity of skin and the factors such as continuous appearance of Resistant strain, superficial mycosis remains a kind of obstinate refractory, the dermatosis that is easy to recur.
According to data, reach 78% at the mycotic sickness rate of China.Mycosis is divided into superficial mycosis and deep mycosis two big classes, mycotic infection of superficial part is called tinea again, being one group of commonly encountered diseases and frequently-occurring disease, is a kind of obstinate refractory, the higher chronic dermatosis of infection rate again, accounts for more than 90% of mycosis total incidence.Infect in the caused tinea at superficial skin fungus, the highest with the prevalence of tinea pedis, be 10 times of the tinea manuum, account for the 50-60% of tinea, cause many miseries to extensive patients.Clinical antifungal drug commonly used comprises econazole, miconazole, clotrimazole and ketoconazole etc. based on imidazoles.Treatment by Chinese herbs is still arranged in addition, but do not accomplish the end in view.
The present invention treats clinically Herba Euphorbiae Humifusae on the basis of superficial mycosis effectiveness, and Herba Euphorbiae Humifusae has been carried out than systematic research: the oral and external preparation of (1) development Herba Euphorbiae Humifusae is used for the treatment of diseases such as tinea capitis, tinea corporis, tinea pedis, tinea versicolor clinically.Clinical observation result with 41 routine superficial fungi patients of Herba Euphorbiae Humifusae extract for treating shows that this medicine significantly improves superficial fungi patient's clinical symptoms and sign, and clinical total effective rate is 97.92%, cure rate is 85.92%, there is no obvious toxic-side effects.(2) be conceived to the clinical effectiveness of Herba Euphorbiae Humifusae, the material base of research Herba Euphorbiae Humifusae and effective site thereof, result of the test shows, water decoction extract is to escherichia coli 078:K80, Salmonella C79-1, and the minimum antibacterial mass concentration of staphylococcus aureus is respectively 10,10,12.5g/L; Herba Euphorbiae Humifusae extract is to the MIC of dermatophytosis
95Value is for 2048ug/ml, to Candida albicans MIC
95Value is 16384ug/ml.The Herba Euphorbiae Humifusae total flavones is to trichophyton gypseum MIC
90Value is for 139.49ug/ml, to trichophyton MIC
90Value is for 110.08ug/ml, to acrothesium floccosum MIC
90Value is for 313.35ug/ml, to microsporon gypseum MIC
90Value is 429.54ug/ml.It is more obvious that the antifungic action that the Herba Euphorbiae Humifusae total flavones is described is got thing than Herba Euphorbiae Humifusae.Important working foundation has been established in this research to the antifungal new drug that Herba Euphorbiae Humifusae effective part group total flavones etc. is made.(3) the Herba Euphorbiae Humifusae total flavones is for investigating index, adopt orthogonal test solvent extraction method, Amberlyst process, microwave assistant extraction, extraction process has been carried out screening test, the result passes through macroporous resin enrichment, the Herba Euphorbiae Humifusae general flavone content is greater than 16% in the dried total solid matters of eluent, the content (7.61%) that is higher than the alcohol extraction dry extract, and eluting rate is greater than 93%, and this method enrichment Herba Euphorbiae Humifusae total flavones is preferably adopted in this explanation.
The extracting method of Herba Euphorbiae Humifusae is a lot, adopt water to carry or alcohol extraction or conventional extracting method such as macroporous resin extraction or organic solvent extraction can obtain the Herba Euphorbiae Humifusae effective part group, comprise flavonoid, tannin, organic acid, sterol, terpene and tannins, coumarin, phenolic acid and liposoluble constituent etc., and effective ingredient comprises ellagic acid, brevifolin, apigenin-7-O-glucoside, luteolin-7-O-glucoside, Quercetin-3-O-galactoside, cupreol, gallic acid, Quercetin, kaempferol, Quercetin-3-O-(2 ", 3 " two-O-Galla Turcica (Galla Helepensis) acyl)-β-D-pyranglucoside, brocade careless plain E (eumaculinE), eumaculinB, eumaculinD.
Summary of the invention
The object of the invention is, a kind of Herba Euphorbiae Humifusae effective site and effective ingredient thereof the purposes as the medicine of preparation antifungic action is provided.Adopt conventional water extraction or alcohol extracting method or macroporous resin extraction or organic solvent extraction method to obtain the Herba Euphorbiae Humifusae effective part group, comprise flavonoid, tannin, organic acid, sterol, terpene and tannins, coumarin, phenolic acid and liposoluble constituent etc., and effective ingredient comprises ellagic acid, brevifolin, apigenin-7-O-glucoside, luteolin-7-O-glucoside, Quercetin-3-O-galactoside, cupreol, gallic acid, Quercetin, kaempferol, Quercetin-3-O-(2 ", 3 " two-O-Galla Turcica (Galla Helepensis) acyl)-β-D-pyranglucoside, brocade careless plain E (eumaculinE), eumaculinB, eumaculinD etc.
According to a conventional method the Herba Euphorbiae Humifusae effective site extracted and Herba Euphorbiae Humifusae effective ingredient are mixed or make oral and external preparation respectively.Said preparation is used for the treatment of mycosis.
Herba Euphorbiae Humifusae effective part group antifungal new drug is intended utilizing nature to enrich Radix seu Caulis Parthenocissi tricuspidatae medical herbs aptitude source, development antifungal uighur medicine preparation and new drug.Be the preparation that the effective part group one Herba Euphorbiae Humifusae total flavones that extracts from the Herba Euphorbiae Humifusae medical material is made, be used for the treatment of diseases such as tinea capitis, tinea corporis, tinea pedis, tinea versicolor clinically, clinical efficacy is remarkable.Said preparation will be promoted the use of as the active drug of treatment mycotic infection of superficial part disease, remove slight illness for tens thousand of patients, bring glad tidings for the mycotic infection of superficial part patient.
The specific embodiment
Embodiment
Herba Euphorbiae Humifusae effective site and effective ingredient thereof are as the purposes of the medicine of preparation antifungic action, adopt conventional water extraction or alcohol extracting method or macroporous resin extraction or organic solvent extraction method to obtain the Herba Euphorbiae Humifusae effective part group, comprise flavonoid, tannin, organic acid, sterol, terpene and tannins, coumarin, phenolic acid and liposoluble constituent etc., and effective ingredient comprises ellagic acid, brevifolin, apigenin-7-O-glucoside, luteolin-7-O-glucoside, Quercetin-3-O-galactoside, cupreol, gallic acid, Quercetin, kaempferol, Quercetin-3-O-(2 ", 3 " two-O-Galla Turcica (Galla Helepensis) acyl)-β-D-pyranglucoside, brocade careless plain E (eumaculinE), eumaculinB, eumaculinD etc.
According to a conventional method the Herba Euphorbiae Humifusae effective site extracted and Herba Euphorbiae Humifusae effective ingredient are mixed or make oral and external preparation respectively.
The test of Herba Euphorbiae Humifusae extract (effective site and effective ingredient thereof) antifungal:
One, the external antifungic action research of Herba Euphorbiae Humifusae extract (effective site and effective ingredient thereof)
Summary purpose: Herba Euphorbiae Humifusae extract is carried out external antifungal experiment, measure its minimal inhibitory concentration (MIC) value.Method: employing NCCLS " the liquid base dilution antifungal susceptibility test reference scheme of gonimoblast shape fungus " (M-38P) scheme measures the MIC value of the clinical common dermatophytosis of 30 strains.The result: Herba Euphorbiae Humifusae extract is to the MIC of different strain in the fungus
90The value scope is 110～429ug/ml.Conclusion: Herba Euphorbiae Humifusae effective site has significant antifungic action.
Key word: Herba Euphorbiae Humifusae extract; Extracorporeal antifungal activity; Minimum inhibitory concentration;
The present invention is by carrying out the minimum inhibitory concentration (MIC) of clinical common dermatophytosis trichophyton, trichophyton gypseum, microsporon gypseum, acrothesium floccosum to Herba Euphorbiae Humifusae extract, understanding is also compared its in-vitro antibacterial effect.
1. experimental apparatus and material
1.1 experimental apparatus: Gilson micropipettor (France); OLYMPUS BH2 microscope; The vertical steriliser of LMQ.R-3260B type (Xinhua Medical Apparatus Co., Ltd. Shandong); Two of electro-heating standing-temperature cultivator: HH-B11; Biohazard Safety Equipment HEAL FORCEHFSafe760S (Shanghai Lishen Scientific Equipment Co., Ltd.).
1.2 experiment material: Herba Euphorbiae Humifusae effective site (XTR) is provided by Uygur medicine institute medicament chamber of autonomous region.Dimethyl sulfoxide (DMSO) (production of Tianjin chemical reagent company limited).Terbinafine (TBF) is provided by promise company.
1.3 experimental strain: the strain source: the bacterial strain that this experiment is adopted is all from Xinjiang medical courses in general big one culture presevation storehouse, attached institute fungus center (XYZ).Actication of culture: will be about from the bacterial strain picking diameter in culture presevation storehouse in the 3mm mycelium with an inocalation method and be inoculated in freshly prepd husky culture medium (SDA) the test tube slant central authorities of protecting, and cultivate after 7-14 days for 26 ℃ and carry out drug sensitive experiment.Experiment bacterial strain uses therefor: trichophyton (T.rubrum) 11 strains; Trichophyton gypseum (T.mentogrophytes) 11 strains; Microsporon gypseum (M.gypseum) 5 strains; Acrothesium floccosum (E.floccosum) 3 strains.Provide by Xinjiang medical courses in general big one culture presevation storehouse, attached institute fungus center (XYZ).
1.4 culture medium: the husky culture medium (SDA) of protecting; RPMI-1640 liquid base.
2. experimental technique
According to NCCLS " the liquid base of gonimoblast shape fungus dilution antifungal susceptibility test reference scheme " (M-38P) scheme measure the minimum inhibitory concentration (MIC) of the climing extract of Artline to clinical common dermatophytosis (30 strain).
2.1 the preparation of antifungal drug diluent: with the Herba Euphorbiae Humifusae extract storing solution, the TBF storing solution is used RPMI-1640 liquid base doubling dilution respectively: the experimental concentration of Herba Euphorbiae Humifusae extract is followed successively by to low by height: 1024ug/ml, 512ug/ml, 256ug/ml, 128ug/ml, 64ug/ml, 32ug/ml, 16ug/ml, 8ug/ml, 4ug/ml, 2ug/ml, the experimental concentration of TBF is followed successively by to low by height: 0.08ug/ml, 0.04ug/ml, 0.02ug/ml, 0.01ug/ml, 0.005ug/ml, 0.0025ug/ml, 0.00125ug/ml, 0.000625ug/ml, 0.0003125ug/ml, 0.000015625ug/ml.
2.2 the preparation of bacteria suspension: the dermatophytosis that will be tried is inoculated in husky guarantor on the culture medium (SDA), cultivates 7-14 days for 26 ℃.Draw the mycelia and the spore on the 0.85%NaCI solution 2ml flushing mycelia surface of sterilization, the flushing liquor that will contain mycelia and spore counts with blood cell counting plate, concentration 1 * 10
5～5 * 10
5Between the CFU/ml, with 50 times to 2 times final concentrations of RPMI-1640 liquid base dilution.
2.3 inoculation: the medicinal liquid of 2 times of final concentrations of 100ul is added in the 96 aseptic orifice plates to low concentration by high concentration respectively by 10 holes, the 1st hole to the, the 11st hole is growth control wells (only add fungus, do not add medicine), and the 12nd hole is a blank hole (fungus, medicine does not add, and has only culture medium).The bacterium inoculation liquid 100ul that mixes up is added respectively in the corresponding micropore, and this will make the antifungal drug of each gradient and bacteria suspension (2 times of final concentrations) are diluted to final concentration respectively at 1: 1.Dermatophytosis: hatch for 26 ℃ and read the result in 7 days.
2.4 result's judgement: through constant temperature culture 24,48,72,96,124 and the 148h observed result, naked eyes are judged under the situation of not stirring, and solution is Clear ﹠ Transparent to be considered as fungus and not to grow fully, and getting fully not, the growth tube lowest concentration of drug is minimum inhibitory concentration (MIC).
3. experimental result
As seen, Herba Euphorbiae Humifusae extract is to the MIC of T.m in the table
90Be 139.49ug/ml, average MIC 87.70ug/ml is to the MIC of T.r
90Be 110.08ug/ml, average MIC 68.16ug/ml is to the MIC of E.f
90Be 313.35ug/ml, average MIC 80.63ug/ml is to the MIC of M.g
90Be 429.54ug/ml, average MIC 194.01ug/ml.
Terbinafine (TBF) is to the MIC of T.m
90Be 0.0236ug/ml, average MIC 0.007ug/ml is to the MIC of T.r
90Be 0.051ug/ml, average MIC 0.02ug/ml is to the MIC of E.f
90Be 0.0176ug/ml, average
MIC 0.0063ug/ml is to the MIC of M.g
90Be 0.0336ug/ml, average MIC 0.015ug/ml
4. discuss
Fungal infection and conditioned pathogen infect and increase gradually in recent years, press for antifungal drug efficient, low toxicity, because the fungal cell belongs to eukaryotic cell, it is only toxic and not involve host cell be difficult to pathogenic fungi to seek a kind of medicine, it is very limited really to be effective to clinical antifungal drug, the antifungal drug of clinical practice at present mainly is the azole antibiotic, yet such antibiotic is prone to drug resistance very much, the natural drug resistance strain constantly increases, therefore from natural drug, seek low toxicity efficiently antifungal drug just become more important.
The present invention adopts NCCLS " the liquid base dilution antifungal susceptibility test reference scheme of gonimoblast shape fungus " (M-38P), and with the positive contrast medicine of Terbinafine, studied the external bacteriostatic activity of Herba Euphorbiae Humifusae extract to 30 strain dermatophytosises, measured its MIC value, the result shows that Herba Euphorbiae Humifusae extract is to the MIC of 4 kinds of dermatophytosises
90The value scope is 110～429ug/ml.This shows that Herba Euphorbiae Humifusae effective site has stronger inhibitory action to clinical common superficial part pathomycete, and is the most responsive to T.r, average MIC value is 68.16ug/ml; Next is E.f, T.m, and its average MIC value is respectively 80.63ug/ml, 87.70ug/ml; Be M.g at last, average MIC value is 194ug/ml.Herba Euphorbiae Humifusae extract to the sensitivity of the trichophyton in the common dermatophytosis than Microsporon height, antimicrobial spectrum by strong to a little less than be followed successively by T.rubrum, E.floccosum, T.mentogrophytes, M.gypseum.
Measured the extracorporeal antifungal activity of positive control drug Terbinafine to 30 strain dermatophytosises simultaneously, as can be known from the results, Terbinafine is to the MIC of common dermatophytosis
90Between 0.005-0.08ug/ml, between the average MIC value 0.005-0.08ug/ml.
Two, the external antifungic action research of Herba Euphorbiae Humifusae extract
[summary] is experimental strain with trichophyton, trichophyton gypseum, microsporon gypseum, acrothesium floccosum and Candida albicans, carries out in vitro the experiment of (invitro) antifungal.The result shows that Herba Euphorbiae Humifusae extract is to the MIC of dermatophytosis
95Value is 2048ug/ml; To Candida albicans MIC
95Value is 16384ug/ml.
[key word] dimension medicine; Herba Euphorbiae Humifusae extract; External antibacterial;
Herba Euphorbiae Humifusae (Euphorbia humifusa Willd) belongs to the Euphorbiaceae euphorbia, effect with heat-clearing and toxic substances removing, cooling blood for hemostasis, its composition mainly contains multiple flavonoid chromocor compounds such as kaempferide, quercetin and glycoside, and other has polyhydric phenols acids such as gallic acid, ellagic acid.From the research situation analysis of present Herba Euphorbiae Humifusae, this medical material have antioxidation, antibiotic, effect such as stop blooding, protect the liver.Antifungic action research about Herba Euphorbiae Humifusae does not appear in the newspapers as yet.This test is by to the research of the external antifungic action of Herba Euphorbiae Humifusae extract, for the further development and use of Herba Euphorbiae Humifusae preparation provide foundation.
1. test material
1.1 it is domestic that Herba Euphorbiae Humifusae in JIUYUE, 1997 is collected in the Zhouzhi County, Shaanxi Province, removes root, dries, it is standby to pulverize the back.
1.2 test strain escherichia coli 078:K80, Salmonella C79-1, staphylococcus aureus is provided by epidemic diseases teaching and research group of Northwest Agricultural University.
2. test method
2.1 the preparation of Herba Euphorbiae Humifusae extract: get the Herba Euphorbiae Humifusae medical material, (60min 40min), merges 2 times extracting solution respectively to add 95% ethanol extraction 2 times.Reclaim ethanol, be condensed into extractum, be Herba Euphorbiae Humifusae extract.
2.2 the extracorporeal bacteria inhibitor test of Herba Euphorbiae Humifusae extract: with trichophyton, trichophyton gypseum, microsporon gypseum, acrothesium floccosum and Candida albicans is experimental strain, carries out in vitro the experiment of (invitro) antifungal.A. culture medium: RPMI1640-bran propylhomoserin, transfer Ph to 7.0 with 0.165mol/L MOPS.B. tried thing: stock solution: the Herba Euphorbiae Humifusae total flavones is diluted to 10mg/ml with sterile purified water, griseofulvin is diluted to 1mg/ml with sterile purified water, stand-by in-20 ℃ of preservations.C. experimental procedure: get above-mentioned stock solution and add in the culture medium, and each pipe is made doubling dilution later on, and establish antibacterial matched group (not dosing) and negative control group (not adding antibacterial).Get the culture fluid 0.1ml of experimental bacteria after one week, add respectively in the fluid medium of each developmental tube except that negative control, through 26 ℃ of one weeks of constant temperature culture, observe every day, observes inhibition or the killing action of Herba Euphorbiae Humifusae total flavones to dermatophytosises such as trichophyton.
3, result
Herba Euphorbiae Humifusae extract is to the MIC of dermatophytosis
95Value is 2048ug/ml; To Candida albicans MIC
95Value is 16384ug/ml.Illustrate that this medicine has remarkable inhibitory action to dermatophytosis and Candida albicans, wherein the inhibitory action to dermatophytosises such as trichophyton, microsporon gypseum, trichophyton gypseum and acrothesium floccosums is stronger.
Four, the clinical observation of Herba Euphorbiae Humifusae extract treatment superficial fungous infection of skin 41 examples
Herba Euphorbiae Humifusae has the effect of heat-clearing and toxic substances removing, cooling blood for hemostasis, and the clinical practice through for many years shows that this medicine is dermopathic evident in efficacy to superficial fungous infection of skin, allergic dermatitis, neurodermatitis, eczema, scabies etc.Use superficial fungous infection of skin 41 examples of Herba Euphorbiae Humifusae extract treatment, now the result be reported as follows:
(1) physical data
This is organized among the 41 routine patients, male's 26 examples, and women's 15 examples, the age is in 9 examples below 20 years old, 21～30 years old 14 example, 31～40 years old 12 example, 41～50 years old 4 example, 2 examples more than 50 years old; The course of disease 1 year with interior 18 examples, 1～2 year 6 example, 2～3 years 4 examples, 3～4 years 4 examples, 4～5 years 3 examples, 5～6 years 2 examples, 4 examples more than 6 years.
(2) observational technique
Case is selected.Be diagnosed as the patient of mycosis (tinea capitis, tinea manus and pedis, tinea unguium, tinea corporis, tinea cruris, tinea versicolor) clinically, can be used as Herba Euphorbiae Humifusae extract clinical observation object, other dermatosiss serious, general of all merging; Merge bacterial infection; Merge severe cardiac, liver, nephrotic and anemia of pregnant woman not as the object of observation.
Observation plan.Ordinary person selects case all by observation plan record symptom, sign and inspection blood, routine urinalysis, liver function, kidney merit etc.Wherein clinical symptoms and sign are all filled in scoring system; Asymptomatic and sign note " 0 " is divided; Erythema appears, pimple, and the dry squama of surface coverage, little itching, true property bacterium positive (+), note " 1 " is divided; Appearance erythema, pimple, chickenpox, play are itched, and fungus is checked and is (++) note " 2 " branch; Erythema mound skin ulcer rash occurs, play is itched, mild bacterial infection, and fungus is checked to (+++) note " 3 " and divides; Erythema mound skin ulcer rash appears, red and swollen pain, and fever, headache, weak, fungus is checked to (++ ++) note " 4 " and divides.
Medication.Herba Euphorbiae Humifusae extract, each 0.5g, every day 3 times.
Efficacy assessment standard.Judge curative effect according to doing well,improving rate before and after the treatment (overall score before the preceding overall score one treatment back overall score/treatment of treatment).Recovery from illness: total doing well,improving rate reaches 100%; Produce effects: total doing well,improving rate 〉=70%; Effectively: total doing well,improving rate 〉=40%; Invalid: total doing well,improving rate＜40%.Recovery from illness, produce effects, effectively add up to total effective rate.
Observed result
(1) Herba Euphorbiae Humifusae extract is to the influence of 41 routine superficial fungi disease (tinea capitis, tinea corporis, tinea versicolor, tinea cruris, tinea manus and pedis) patient's symptoms: table 1 and table 2.
Table 1 Herba Euphorbiae Humifusae extract is to the influence of 41 routine patient's symptoms
Amount to before and after the treatment of table 2 Herba Euphorbiae Humifusae extract and divide relatively
By table 1 and table 2 as seen, Herba Euphorbiae Humifusae extract can significantly improve skin superficial fungi patient clinical symptoms and signs such as tinea manus and pedis.Compare " seven " method of inspection of (own control relatively) with consubstantiality and carry out statistical procedures, significant differences p＜0.001 is arranged before and after the treatment.
Table 3 Herba Euphorbiae Humifusae extract clinical observation result
By table 3 as seen, among this group superficial fungi patient, recovery from illness accounts for 85.92%, effectively accounts for 12.0%, invalidly accounts for 2.25%, total effective rate 97.92%.
(2) untoward reaction 41 routine patient's observed results show, blood, urine, liver, all no abnormal variation of kidney merit before and after the treatment, and lose any toxic and side effects.
Discuss
Uygur medicine is thought the ANOMALOUS VARIATIONS of four kinds of body fluid of human body (bile matter, blood matter, phlegmatic temperament, black gallbladder matter) on quality and quantity, and body fluid balance imbalance etc. is that the inherent key factor of disease people takes place.
Superficial fungi disease (tinea capitis, tinea manus and pedis, tinea unguium, tinea corporis, tinea versicolor ...) be under the unusual phlegmatic temperament influence black gallbladder matter to be piled up in the patient skin somewhere, influence skin-nourishing power, cause the generation of superficial fungi disease.Treat this type of disease, at first must prohibit against alcoholic drinks other irritable foods of fasting, simultaneously, according to the situation of unusual body fluid in patient's body, take corresponding body fluid maturing agent and the pathogenic body fluid scavenger of causing a disease, make the body fluid state that restores balance, recover the analeptic of patient's organ dysfunction etc. then.
Herba Euphorbiae Humifusae extract has the effect of heat-clearing and toxic substances removing, cooling blood for hemostasis, use 41 routine superficial fungi patients' of Herba Euphorbiae Humifusae extract treatment clinical observation result to show, this medicine significantly improves superficial fungi patient's clinical symptoms and sign, clinical total effective rate is 97.92%, cure rate is 85.92%, and effective percentage is 12.0%, and invalid is 2.25%, no obvious toxic-side effects is the good medicine of treatment superficial fungi disease.
Claims (1)
1, a kind of Herba Euphorbiae Humifusae extract is as the purposes of unique crude drug in the medicine of the anti-superficial mycosis of preparation, the preparation method that it is characterized in that Herba Euphorbiae Humifusae extract is: get the Herba Euphorbiae Humifusae medical material and add 95% ethanol extraction 2 times, be respectively 60 minutes, 40 minutes, merge 2 times extracting solution, reclaim ethanol, be condensed into extractum, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101008171A CN100540013C (en) | 2006-06-27 | 2006-06-27 | Herba Euphorbiae Humifusae effective site and effective ingredient thereof are in the purposes of the medicine of preparation antifungic action |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101008171A CN100540013C (en) | 2006-06-27 | 2006-06-27 | Herba Euphorbiae Humifusae effective site and effective ingredient thereof are in the purposes of the medicine of preparation antifungic action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1895331A CN1895331A (en) | 2007-01-17 |
| CN100540013C true CN100540013C (en) | 2009-09-16 |
Family
ID=37608069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101008171A Expired - Fee Related CN100540013C (en) | 2006-06-27 | 2006-06-27 | Herba Euphorbiae Humifusae effective site and effective ingredient thereof are in the purposes of the medicine of preparation antifungic action |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100540013C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102429951B (en) * | 2011-12-01 | 2013-12-18 | 燕山大学 | Flavone-saponin extract of humifuse euphorbia herb and application thereof |
| CN103622955B (en) * | 2013-12-09 | 2016-01-06 | 新疆维吾尔自治区维吾尔医药研究所 | Ellagic acid is being treated and is being prevented the application in the medicine of Human Fungi infection |
-
2006
- 2006-06-27 CN CNB2006101008171A patent/CN100540013C/en not_active Expired - Fee Related
Non-Patent Citations (6)
| Title |
|---|
| 地锦类中草药的化学成分和药理研究概况. 褚小兰等.中国野生植物资源，第17卷第2期. 1998 |
| 地锦类中草药的化学成分和药理研究概况. 褚小兰等.中国野生植物资源，第17卷第2期. 1998 * |
| 地锦草的研究进展. 朱英.现代中药研究与实践，第17卷第5期. 2003 |
| 地锦草的研究进展. 朱英.现代中药研究与实践，第17卷第5期. 2003 * |
| 正交试验法优选地锦草的提取工艺. 李肖玲等.中国中医药信息杂志，第12卷第4期. 2005 |
| 正交试验法优选地锦草的提取工艺. 李肖玲等.中国中医药信息杂志，第12卷第4期. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1895331A (en) | 2007-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Faiza Aslam et al. | Antibacterial activity of various phytoconstituents of neem. | |
| Kaur et al. | Anti-acne activity of acetone extract of plumbago indica root | |
| Wang et al. | Antibacterial mechanism of the synergistic combination between streptomycin and alcohol extracts from the Chimonanthus salicifolius SY Hu. leaves | |
| Taiwo et al. | The biocidal and phytochemical properties of leaf extract of Cassia occidentalis Linn | |
| CN101209254A (en) | New use of polyhydroxy galloyl-beta-D-glucose derivatives | |
| Cui et al. | Stimulation of dragon's blood accumulation in Dracaena cambodiana via fungal inoculation | |
| Singh et al. | Antibacterial activity of seed extracts of Argemone mexicana L. on some pathogenic bacterial strains | |
| CN100540013C (en) | Herba Euphorbiae Humifusae effective site and effective ingredient thereof are in the purposes of the medicine of preparation antifungic action | |
| Adeshina et al. | Antimicrobial activity of the aqueous and ethyl acetate sub-fractions of Alchornea cordifolia leaf | |
| Jahan et al. | Antimicrobial potential of gemmo-modified extracts of Terminalia arjuna and Euphorbia tirucalli | |
| CN109820887B (en) | Composition with function of treating beriberi and application thereof | |
| CN103768298A (en) | Disinfectant for clinical laboratory and preparation method thereof | |
| Olusola et al. | Preliminary phytochemical and antimicrobial screening of the leaf extract of Cassia singueana Del. | |
| CN105031553A (en) | Medicine composition for treating dog dermatomycosis and preparation method and application thereof | |
| CN110623999B (en) | Environment-friendly preparation method and application of composition containing anti-inflammatory active ingredients | |
| CN104857116B (en) | Application of the Chinese medicine garden burnet in preparing antifungal medicine synergist | |
| CN103638055B (en) | Polyhachis vicina Roger extract and and antifungal pharmaceutical purposes thereof | |
| CN103251636A (en) | Medicament for treating Candida infections and diseases caused by Candida, and preparation method thereof | |
| Kini et al. | Sporotrichosis in India: first authentic case report from the north-western region and a critical literature review | |
| CN112245566A (en) | New application of scutellaria flavonoid compound and/or metal ion complexing agent in synergism of polymyxin antibiotics antibacterial action | |
| Shetty et al. | Antimicrobial activity of Anisochilus carnosus (LF) Wall against the Human gastric pathogen Helicobacter pylori | |
| CN109700858A (en) | Rhizoma Polygoni suffulti is preparing the application in antifungal drug and its synergist | |
| CN107601682A (en) | Bacterial micro-organism cleanser in a kind of sewage | |
| Liao et al. | Natural compounds targeting mitochondrial dysfunction: emerging therapeutics for target organ damage in hypertension | |
| CN113082150B (en) | Application of effective part of deer medicine in preparing antifungal medicine and synergist thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090916 Termination date: 20120627 |